Abbott India Ltd rises for third straight session
NiveshIQ
NSE: ABBOTINDIA · Healthcare
Abbott India Ltd.
₹25,550.00▲ ₹290.00 (+1.15%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on ABBOTINDIA. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Abbott India Ltd.
Abbott India Limited, a subsidiary of Abbott Capital India, is a diversified pharmaceutical company headquartered in Mumbai that offers a broad portfolio spanning gastroenterology, women’s health, metabolic disorders, hypothyroidism, CNS, vaccines, and consumer care products. In FY27 Q2, the company reported revenues of ₹7,004 crore and a net income of ₹1,615 crore, reflecting steady growth driven by its flagship anti‑infectives and metabolic segments. Recent developments include the appointment of Sudarshan Jain as chairman and the resignation of Company Secretary Sangeeta Shetty, signalling a focus on governance and strategic leadership. Abbott India’s competitive position is reinforced by its strong R&D pipeline, extensive distribution network, and brand recognition in both branded and
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹5,849 Cr +9.30% | ₹6,410 Cr +9.60% | ₹6,929 Cr +8.10% |
| EBITDA Margin | 24.86% | 26.44% | 28.40% |
| Net Profit | ₹1,201 Cr +26.60% | ₹1,415 Cr +17.80% | ₹1,552 Cr +9.70% |
| EPS | ₹565.30 | ₹665.63 | ₹730.39 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
‘We’ll fully ban Sharia law in Texas…’: Gov. Greg Abbott delivers fiery message from RNC stage
Abbott India Q2 Results FY27: Date and Expectations
🔒
+ 3 more stories about Abbott India Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q1FY27 results: revenue ₹1, 814 Cr, PAT ₹429 Cr, EPS ₹201.66, EBITDA margin 33.0%. Growth context: revenue QoQ +6.1%, PAT QoQ +8.5%. Street verdict: inline, revenue surprise -2.8%, PAT surprise -1.0%.
Recent corporate activity highlights product launches, approvals, and therapy-mix improvement and new capacity addition ...
FY26 (last completed FY): revenue ₹6, 929 Cr, PAT ₹1, 552 Cr, EBITDA margin 28.4%, EPS ₹730.39. Year-on-year: revenue Yo...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for ABBOTINDIA
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track ABBOTINDIA alongside your other holdings
Unlock full ABBOTINDIA research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Abbott India Ltd.?
NiveshIQ detects active intelligence signals for Abbott India Ltd. (ABBOTINDIA) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Abbott India Ltd.?
Abbott India Ltd. operates in the Healthcare sector with a market capitalisation of ₹5,895,618.6L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.